How to minimize budgets on commercial antibodies?

5^th International Conference on Biomarkers & Clinical Research

April 15-17, 2014 St. Hilda’s College - University of Oxford, UK

Jan Voskuil

Scientific Tracks Abstracts: J Mol Biomark Diagn

Abstract :

M any commercial antibodies being on the market for decades turn out unfit for the ever increasing number of different applications they are required for. The search for fit-for-purpose antibodies is on. The traditional focus on monoclonal antibodies do not always match today?s highly specific requirements. Alternatives are hard to find, and a lack of adequate knowledge on the many types of antibodies and vendors causes extensive financial expenditure to buy and try. This presentation aims to assist the biomarkers world in the decision making on antibody purchases in the most cost- effective manner.

Biography :

Jan Voskuil is the Chief Scientific Officer at antibody manufacturer Everest Biotech in Oxfordshire, UK. After specializing in prokaryotic cell biology through his Ph.D. program in Amsterdam, Netherlands, and a postdoc position at Stanford, California, he switched to the science of neurodegenerative diseases at Oxford, UK through postdoc positions at Dunn School of Pathology and at MRC and through a leading position at the Alzheimer drug discovery company Synaptica. He subsequently gained experience in a GLP-regulatory environment in CRO companies both in Oxfordshire and Cambridgeshire, validating assays in Flow Cytometry and ELISA platforms and writing SOPs. His extensive experience with generating and characterizing monoclonal and polyclonal antibodies in combination with accrued knowledge on most immunoassays in academic and commercial environments made him the ideal candidate to take charge in putting Everest Biotech on the global map by ever raising the quality and size of its catalogue and by delivery of adequate technical support. As a result, Everest antibodies are currently part of most globally well-known catalogues, and its products are increasingly recognized as useful alternatives to unfit monoclonal antibodies